“We therefore plan to initiate a Phase 3 program over the next six months, and you'll learn more about that.”

In context

“lts, our vaccination was in Europe and outside of the country is quite limited. Now that we see Prevnar 20 registered and validated by VTC, we see significant pickup. And let me give you an example. In Germany, we got VTC recommendations for 60 and above, all-comers and at risk, from 18 to 59. And there, in Germany, since the beginning of the year, we see significant growth. We see that we will have similar trends in other major markets in Europe. Albert Bourla: Thank you. And Chris? Chris Boshoff: Thank you very much for the question on KAT6. KAT6 is a first in category medicine. We’re very proud that this medicine was conceptualized and discovered at our laboratories in Ohio. As you’ve seen with the most recent data, objective response rate over 35% durable responses and well tolerated. We therefore plan to initiate a Phase 3 program over the next six months, and you’ll learn more about that. But thank you for the question. We’re also excited about KAT6. Albert Bourla: Thank you. We are very excited about it. Next question, please. Operator: Our next question comes from Carter Gould with Barclays. Carter Gould: Good morning. Thank you for taking the question. I guess first one, just a clarification. I guess when we think about the PK danuglipron data, the top line, on a month ago, are we going to see any of that data prior to the dose optimization data reading out early next year? And then as we think about timelines for danuglipron, some of your European peers have talked about potentially moving faster. And I think some of the timelines that are generally thrown out there, including potentially reaching market as early as 2028. Did Pfizer have sort of similar plans or think”